Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases

Core Insights - Plus Therapeutics, Inc. is advancing its lead compound REYOBIQ™ for treating central nervous system cancers, with new data to be presented at an upcoming conference [1][4] Group 1: Clinical Data and Results - The abstract presented at the Nuclear Medicine and Neurooncology conference highlights data from the Phase 1 ReSPECT-LM trial, showing a dose-dependent increase in absorbed radiation dose, reaching 253Gy in Cohort 5 [2] - Among 16 patients evaluated, 5 (31%) exhibited a partial response, while 7 patients showed stable disease, resulting in a Clinical Benefit Rate of 75% [2] - Physician evaluations indicated a decrease in disease findings in 2 of 14 patients (14%), with 10 patients maintaining stable findings, leading to an 86% Clinical Benefit Rate [2] - No dose-limiting toxicity was observed in the first four cohorts, with a grade 4 DLT (thrombocytopenia) noted in Cohorts 5 and 6 [2] Group 2: Mechanism and Potential - RNA sequencing of leptomeningeal metastases (LM) cells indicated early apoptosis induction and an immune response, with T cell increase by Day 28 [3] - REYOBIQ™ is designed to deliver targeted high-dose radiation effectively, potentially improving outcomes for CNS cancer patients compared to existing therapies [6] Group 3: Background on Leptomeningeal Metastases - Leptomeningeal Metastases (LM) is a severe complication of cancer, affecting approximately 5% of cancer patients, often leading to terminal outcomes [5] - There are currently no FDA-approved therapies specifically for LM, highlighting a significant unmet medical need [5] Group 4: Company Overview - Plus Therapeutics is focused on developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes programs for LM and recurrent glioblastoma [7] - The company has established a supply chain through strategic partnerships to support the development and potential commercialization of its products [8]